JPMorgan Chase & Co. Cuts Stock Position in Smith & Nephew plc (NYSE:SNN)

JPMorgan Chase & Co. trimmed its position in Smith & Nephew plc (NYSE:SNN) by 90.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,977 shares of the medical equipment provider’s stock after selling 314,228 shares during the period. JPMorgan Chase & Co.’s holdings in Smith & Nephew were worth $1,027,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC boosted its holdings in shares of Smith & Nephew by 160.0% in the third quarter. GAMMA Investing LLC now owns 2,257 shares of the medical equipment provider’s stock valued at $70,000 after acquiring an additional 1,389 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Smith & Nephew by 92.5% in the second quarter. EverSource Wealth Advisors LLC now owns 2,454 shares of the medical equipment provider’s stock valued at $61,000 after purchasing an additional 1,179 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Smith & Nephew by 74.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,025 shares of the medical equipment provider’s stock valued at $94,000 after purchasing an additional 1,290 shares in the last quarter. Blue Trust Inc. increased its position in Smith & Nephew by 460.5% during the 3rd quarter. Blue Trust Inc. now owns 4,658 shares of the medical equipment provider’s stock worth $145,000 after purchasing an additional 3,827 shares during the period. Finally, Coerente Capital Management purchased a new position in shares of Smith & Nephew during the 3rd quarter worth approximately $202,000. 25.64% of the stock is owned by institutional investors and hedge funds.

Smith & Nephew Trading Up 0.4 %

SNN opened at $25.09 on Friday. Smith & Nephew plc has a 1-year low of $23.65 and a 1-year high of $31.72. The stock’s 50 day simple moving average is $25.03 and its 200 day simple moving average is $27.73. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51.

Analyst Upgrades and Downgrades

SNN has been the topic of a number of recent analyst reports. StockNews.com lowered Smith & Nephew from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Finally, Berenberg Bank cut shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Wednesday, November 6th.

About Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.